sleep disorder
The South Korean company now plans to expand the application of its AI to diagnose other medical conditions, including heart and neurological disorders.
It provides recommendations for sleep timing based on their work and personal calendar and records of sleep/wake times and mood.
They seek to identify digital predictive biomarkers of narcolepsy and excessive daytime sleeping.
It has been approved as a prescription-only software-as-a-medical device in the US.
As part of the agreement, SoftBank will research market opportunities for the digital therapeutic, and it can negotiate an exclusive commercialization deal in Japan.
HoneyNaps claims its software provides more accurate readings than conventional auto-scoring.